Journal
PEPTIDES
Volume 130, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2020.170332
Keywords
Pituitary adenylate cyclase-activating polypeptide; Stroke; Dementia; Alzheimer's disease; Amyloid beta protein; Neurotrophin
Funding
- JSPS KAKENHI [16OH2684, 18OH5386]
Ask authors/readers for more resources
Evidence shows that pituitary adenylate cyclase-activating polypeptide (PACAP) improves stroke outcomes and dementia. The blood-brain barrier (BBB) controls the peptide and regulatory protein exchange between the central nervous system and the blood; the transport of these regulatory substances across the BBB has been altered in animal models of stroke and Alzheimer's disease (AD). PACAP is a powerful neurotrophin that can cross the BBB, which may aid in the therapy of neurodegenerative diseases, including stroke and AD. PACAP may function as a potential drug in the treatment, prevention, or management of stroke and AD and other neurodegenerative conditions. Here, we review the effects of PACAP in studies on stroke and dementias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available